Working to Eradicate Gynecologic Cancers

PS2
Featured Poster Session II: Predictors of Outcomes in Ovarian Cancer/Translational Science

Sunday, March 23, 2014: 6:30 AM-7:30 AM
Room 13-16 (Tampa Convention Center)
Description:
Featured Poster Session Moderator:  John B. Liao, MD, PhD, University of Washington, Seattle, WA
6:30 AM
Moderator Introductions
J. B. Liao
University of Washington, Seattle, WA
 
6:35 AM
41 - Featured Poster
The impact and interaction of preoperative disease burden, complex surgery, and residual disease in patients with advanced stage ovarian cancer and the effect on on patient survival: A GOG 182 analysis
T. C. Krivak1, A. Miller2, B. J. Rungruang3, N. S. Horowitz4, S. D. Richard5, N. Rodriguez6, M. A. Bookman7, C. A. Hamilton8 and G. L. Maxwell9
1Western Pennsylvania Hospital, Pittsburgh, PA, 2Gynecologic Oncology Group, Buffalo, NY, 3Georgia Reagents University, Evans, GA, 4Harvard University, Boston, MA, 5Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA, 6Loma Linda University Medical Center, Loma Linda, CA, 7University of Arizona Cancer Center, Tucson, AZ, 8Walter Reed National Military Medical Center, Bethesda, MD, 9Inova Fairfax Hospital, Falls Church, VA
 
6:37 AM
42 - Featured Poster
BRCA1/2 protein expression as a potential marker of the BRCAness syndrome in ovarian cancer
J. C. Mejia
Instituto Nacional de Cancerlogia of Mexico, Mexico City, Mexico
 
6:39 AM
43 - Featured Poster
Identification of candidate circulating cisplatin resistance biomarkers from epithelial ovarian carcinoma cell secretomes
P. N. Teng1, G. Wang1, B. L. Hood1, K. A. Conrads1, C. A. Hamilton2, G. L. Maxwell3, K. M. Darcy1 and T. P. Conrads1
1Gynecologic Cancer Center of Excellence, Annandale, VA, 2Walter Reed National Military Medical Center, Bethesda, MD, 3Inova Fairfax Hospital, Falls Church, VA
 
6:41 AM
44 - Featured Poster
MicroRNA 206 is associated with longer overall survival and platinum sensitivity in serous epithelial ovarian cancer
A. Jewell1, K. Watters1, A. K. Mitra2, R. Bao1, C. Y. Chiang1, M. Curtis1, J. Andrade1, S. D. Yamada1 and E. Lengyel1
1University of Chicago, Chicago, IL, 2Indiana University, Bloomington, IN
 
6:43 AM
45 - Featured Poster
The significance of prior tubal occlusion in uterine papillary serous carcinoma
C. C. Nitschmann1,2,3, M. J. Worley Jr.1,3, K. Prescott1,3 and C. M. Feltmate3,4
1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Dana Farber Cancer Institute, Boston, MA, 4Brigham and Women's Hospital and Harvard University, Boston, MA
 
6:45 AM
46 - Featured Poster
Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced-stage serous ovarian or primary peritoneal cancer: a Gynecologic Oncology Group (GOG) study
T. C. Krivak1, D. Tritchler2, K. N. Moore3, K. Kaufman4, H. Lankes2, D. K. Armstrong5, M. J. Birrer6, M. F. Brady7 and M. A. Bookman8
1Western Pennsylvania Hospital, Pittsburgh, PA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3The University of Oklahoma, Oklahoma City, OK, 4University of Oklahoma, Oklahoma City, OK, 5Johns Hopkins Kimmel Cancer Center, Baltimore, MD, 6Massachusetts General Hospital Cancer Center/Harvard University, Boston, MA, 7University of Buffalo, Buffalo, NY, 8University of Arizona Cancer Center, Tucson, AZ
 
6:47 AM
Discussant
V. L. Bae-Jump
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
 
6:52 AM
47 - Featured Poster
Developing novel aldehyde dehydrogenase inhibitors to target ovarian cancer stem cells
L. J. Hong1, I. Chefetz1, K. Yang1, C. N. Landen Jr.2, S. D. Larsen1 and R. J. Buckanovich1
1University of Michigan, Ann Arbor, MI, 2University of Alabama at Birmingham, Birmingham, AL
 
6:54 AM
48 - Featured Poster
Wound healing gone awry: role for platelets in tumor growth after antiangiogenic therapy
J. N. Bottsford-Miller1, M. Taylor1, H. J. Dalton1, R. L. Stone2, A. M. Nick1, A. N. Davis1, B. Zand1, R. A. Previs1, V. Afshar-Kharghan1 and A. K. Sood1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2University of Arkansas for Medical Sciences, Little Rock, AR
 
6:56 AM
49 - Featured Poster
Pathogenesis of ARID1A-driven gynecologic cancer
J. I. Risinger1, Y. Shoji1, K. A. Conrads2, R. Challa1, B. L. Hood2, G. Wang2, K. M. Darcy2, C. A. Hamilton3, G. L. Maxwell4 and T. P. Conrads2
1Michigan State University, Grand Rapids, MI, 2Gynecologic Cancer Center of Excellence, Annandale, VA, 3Walter Reed National Military Medical Center, Bethesda, MD, 4Inova Fairfax Hospital, Falls Church, VA
 
6:58 AM
50 - Featured Poster
Natural killer cells derived from human-induced pluripotent stem cells: an “off the shelf” strategy for killing ovarian cancer
M. A. Geller, D. L. Hermanson, D. A. Knorr, L. A. Bendzick, L. J. Pribyl and D. S. Kaufman
University of Minnesota, Minneapolis, MN
 
7:00 AM
Discussant
D. Khabele
Vanderbilt University, Nashville, TN
 
7:05 AM
51 - Featured Poster
More is not always better: thrombocytosis contributes to impaired chemotherapy response in ovarian cancer
J. N. Bottsford-Miller1, M. Taylor1, H. J. Dalton1, R. L. Stone2, A. M. Nick1, A. N. Davis1, B. Zand1, R. A. Previs1, V. Afshar-Kharghan1 and A. K. Sood1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2University of Arkansas for Medical Sciences, Little Rock, AR
 
7:07 AM
52 - Featured Poster
Pharmacologic inhibition of the DNA damage response kinases ATR (ataxia telangiectasia and rad3 related) and ATM (ataxia telangiectasia mutated) broadly sensitizes diverse subtypes of gynecologic cancer cells to ionizing radiation
N. W. Bateman1, P. N. Teng1, K. A. Conrads1, C. A. Hamilton2, G. L. Maxwell3, C. J. Bakkenist4 and T. P. Conrads1
1Gynecologic Cancer Center of Excellence, Annandale, VA, 2Walter Reed National Military Medical Center, Bethesda, MD, 3Inova Fairfax Hospital, Falls Church, VA, 4University of Pittsburgh, Pittsburgh, PA
 
7:09 AM
53 - Featured Poster
Inhibition of gamma-secretase activity in combination with carboplatin and paclitaxel precludes uterine papillary serous carcinoma growth in a primary human xenograft model
J. W. Groeneweg, T. R. Hall, L. Zhang, M. Kim, V. F. Byron, C. M. DiGloria, R. Tambouret, R. Foster, B. R. Rueda and W. B. Growdon
Massachusetts General Hospital, Boston, MA
 
7:11 AM
54 - Featured Poster
Development of a Rucaparib response signature that shows in vitro predictive value to the PARP inhibitors, ABT-888 and Olaparib in ovarian cancer cells
S. S. Al Rubaish1, Y. Xiong1, D. Marchion1, F. Abbasi1, S. H. Bush2, I. Ramirez2, N. Bou Zgheib2, P. L. Judson Lancaster1, R. M. Wenham1 and J. M. Lancaster1
1H. Lee Moffitt Cancer Center, Tampa, FL, 2University of South Florida College of Medicine, Tampa, FL
 
7:13 AM
Discussant
J. B. Liao
University of Washington, Seattle, WA
 
7:18 AM
Question & Floor Discussion
 
See more of: Featured Poster Session
<< Previous Course | Next Course >>